Micaela

ceo @metanova_labs / metaprogramming / decentralization / ai drug design / existential aesthetics

[Micaela @micaelabazo]

2026 is indeed proving to be an inflection point.

the pace of progress across the field continues to validate our conviction that AI will fundamentally reshape how medicines are discovered.

at the same time, the progress inside @metanova_labs reinforces our belief that decentralized, incentive-driven networks have a meaningful role to play in that future.

this half marked a few important milestones for us, most importantly, moving beyond computational discovery.

couldn't be more excited for the months ahead!

[METANOVA @metanova_labs]

https://t.co/1fuleBo3iH

[METANOVA @metanova_labs]

The new https://t.co/l3s3hIg7ds is now live.

Take a deeper look at:
• Our approach to AI drug discovery
• NOVA's competition architecture
• How value is created across the platform
• Partnership opportunities

Thank you to @14islands for bringing the redesign to life.

[Autism Capital 🧩 @AutismCapital]

People are already paranoid that their devices are reading their thoughts (they are). Imagine now. God help us all not even thoughts are safe anymore. Jesus Christ.

[Micaela @micaelabazo]

every time i interact with a bank or government i get more pilled.

u mean… i owe u half no matter where i live?

ur website only works during business hours?

it will take 2-3 days to transfer?
months to set up?

[more egregious examples redacted]

it’s either inevitable global adoption or irreversible forking.

not much of a gamble to bet the digitally native side wins.

[Micaela @micaelabazo]

appreciate not only this s/o but also every inevitably deep convo @pennapdr and i have had with @capradavis and @Old_Samster

it’s ultra rare to have an investment group DD domain-specific micro and macro

overall huge validation for building on #bittensor and the @CrucibleLabs team’s role in taking us to the next level

[Chris Davis @capradavis]

1) cracked team with strong industry experience + connections (easily the top 1-2 in all of desci imo), 2) structural advantage in accuracy, cost and speed in early stage discovery that scales in tandem with advancements in frontier, open-source model releases (boltz-2, boltzgen), 3) insane blueskies scenario (token would like 5x overnight lol), but still a very good base case as well, 4) actually doing real science (i say this as a desci lover)

[Micaela @micaelabazo]

@lbolord @capradavis @metanova_labs dms open

[Micaela @micaelabazo]

the trend is clear: more restrictions, less access.

the opportunity cost: discoveries that never happen.

building permissionless infrastructure for scientific innovation is more important than ever.

humans are notoriously bad at reasoning over long time horizons that extend beyond tribal boundaries.

gates of all kinds may grant companies and governments the illusion of protection, but they rarely work and ultimately reduce the probability of a breakthrough.

@metanova_labs we're building a decentralized global engine for drug discovery.

we're not waiting for the gates to lock to get started.

[METANOVA @metanova_labs]

Geopolitical conservatism in biotech risks becoming anti-progress.

Biosecurity matters but scientific talent is globally distributed and the tools for discovery should be too.

@metanova_labs mission is more important than ever.

Decentralized, permissionless infrastructure isn't just an ideological position — it's a practical response to a growing problem that ultimately affects all of us.

Immigration to the global centers where institutions, capital, and infrastructure are concentrated is harder than ever.

At the same time, access to frontier AI is increasingly determined by jurisdiction.

As evidenced by @AnthropicAI recent restrictions on Fable and others, the tools that enable scientific discovery are becoming concentrated within a relatively small number of (or single) countries.

This has implications for who can contribute to scientific innovation and from where.

Roughly 2/3 of Nobel science laureates were not born in the United States, and approximately 40% of U.S. Nobel science prizes awarded since 2000 went to immigrants.

Meanwhile, proposals such as a $100k H-1B fee, travel restrictions affecting dozens of countries, and compute export controls under the BIS AI Diffusion Framework are making participation in frontier research increasingly unequal.

If similar restrictions had existed throughout the last century, many of the discoveries, companies, and medicines we rely on today may never have emerged.

#Bittensor offers a market-driven alternative for coordinating talent, capital, compute, and scientific innovation across borders.

[Pedro Penna @pennapdr]

From openly blocking models for relevant pharma problems, to silently reducing Fable capabilities for frontier AI research, to now fully blocking the use of Fable, the signal is clear.

There has never been a more relevant and exciting time to be building in the open, right at the critical intersection of AI and drug development. This is where incentivised open science will lead.

#Bittensor

[Micaela @micaelabazo]

join us in montreal this september @ExploitSummit

[Exploit Summit @ExploitSummit]

NOVA coordinates a network of Bittensor miners to screen molecules, design nanobodies, and develop algorithms that outperform published drug discovery techniques. @metanova_labs is using this as a starting point for their and their partners' R&D.

This is what the Intelligence Frontier looks like.

Catch @micaelabazo, CEO and Co-founder, sharing their work on the Exploit stage in September 👇

[Micaela @micaelabazo]

@MaxScore rooting for you and the holy triangle

[The TAO Daily @taodaily_io]

Micaela @micaelabazo, CEO of NOVA (SN68) at PoT:

"We're part of the most important investment category, potentially the most rewarding, because our success will not just be measured in dollars, euros, or $TAO, but also HUMAN LIFE."

📽️ Credit: @proofoftalk @SubnetSummerTAO

[Micaela @micaelabazo]

ICYMI: how @metanova_labs is incentivizing quality and novelty in virtual drug discovery through permissionless competition.

[WallStreetBets @wallstreetbets]

Bittensor $TAO alpha live right now 👀

https://t.co/SIXj5Ocxpo

[Micaela @micaelabazo]

really exciting to present @metanova_labs vision and all of our progress to a packed room @proofoftalk

[Micaela @micaelabazo]

@WSquires lol i have light sensitivity from a concussion kkk

[METANOVA @metanova_labs]

We have found crypto to be incredibly effective at incentivizing quantity AND quality with the right incentive design.

For example in only 2 weeks running our nanobody design competition we saw:
• Binding confidence: up ~3x from first to last submission
• Structural fit: uncertainty at the interface dropped by nearly half
• Hydrogen bonds: grow steadily across all designs.

https://t.co/6zWIy1tV9Q

As well as in our chemical search algorithm competition, where a miner introduced an optimization strategy never applied to drug discovery before (not just quality but novelty).

This strategy has continued to be improved across challenges and consistently outperforms a published benchmark across different targets.

https://t.co/A0PdDwujs2

You can see our progress live on our dashboard:
https://t.co/EevQyg0ctx

[Micaela @micaelabazo]

newfound hope for a diagnosis that was once synonymous with a statistical death sentence.

the value of these results is immeasurable.

health is the highest-leverage investment of our time, attention, technology, and capital.

@metanova_labs we are building a new decentralized approach to drug discovery with the goal of making that investment more efficient, open, and capable of coordinating different forms of intelligence toward therapeutic progress.

[Bo Wang @BoWang87]

Today at #ASCO26, more results about the newest clinical trial of daraxonrasib: In the Phase III RASolute-302 trial, a once-daily RAS(ON) inhibitor nearly doubled median overall survival (13.2 vs 6.7 months) and reduced the risk of death by ~60% versus chemotherapy in previously treated metastatic pancreatic cancer.

KRAS was once considered “undruggable.” This is what persistence in science looks like.

A landmark moment for targeted therapy and for patients who desperately need better options. #CancerResearch #PancreaticCancer

[Dave Messina @DaveMessina]

Health/bio is the greatest investment opportunity of this decade.

[James Sinka - Boston & SF @jamessinka]

Daraxonrasib ~doubles the survival rate of patients with metastatic pancreatic cancer.

13.2 months for patients taking daraxonrasib versus 6.7 months for those on standard chemotherapy.

These results are stellar, standing ovation is due.

[Micaela @micaelabazo]

always a pleasure chatting with @haitzu about @metanova_labs and how we're decentralizing AI drug discovery

full episode: https://t.co/Hn0Swj807Q

[Jack Ai-Leung @haitzu]

Nova (SN68) is the #1 horse for healthcare on Bittensor

Sat down with founder @micaelabazo on why this is the mission for her and her cofounders lives

The truth is that pharma has only just begun on their AI revolution, and the whole ecosystem is being upended

Anyone from around the world can contribute to the progression of life via Bittensor

Robotics, Data Centres, Energy

What about the fight for humanity?

I discuss all things opensource, AI and social change on Supercyle Podcast. Only available on Youtube/Spotify

Timestamps:

00:00 Intro

02:19 Intro to Pharma & Drug Discovery

05:40 Price of Healthcare Innovation

09:18 Advantages of Decentralized Pharma Research

18:53 Subnets as a Competition for Drug Discovery

27:12 Micaela Story

37:21 Future for Biotech Startups

41:09 2026 Roadmap

43:44 Lessons from Bittensor

[Micaela @micaelabazo]

@DrocksAlex2 let me introduce u to @42salamandas as well

[Micaela @micaelabazo]

see you in paris

[Proof of Talk @proofoftalk]

We’ve assembled a lineup of individual Subnet Keynotes from some of the most exciting teams building on Bittensor.

Each keynote will spotlight a different part of the subnet economy:
@micaelabazo, @metanova_labs — decentralised AI for pharma and drug discovery.
@0xcarro, @TargonCompute — confidential compute infrastructure through TEEs.
@tm0klc, @manakoai — vision models and Manako, turning Bittensor-powered computer vision into enterprise use cases.
@mast3rdubs, @hippius_subnet — decentralised storage and cloud infrastructure.
@kenjon, @bitmind — deepfake detection and AI content verification.
@shardiban, @oroagents — the open arena for AI agents.

June 2-3, Bittensor Track at Proof of Talk.